Login

Auspex Pharmaceuticals, Inc. 4/A SEC Filings

Filed On Filing
17 Feb 2015 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 20,670 shares ($1.24M) · Sold 53,100 shares ($3.28M)

01 Dec 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Acquired 2 Put Option (right to sell) (Open Market Purchase) ($274K) · Disposed of 2 Call Option (right to buy) (Open Market Sale) ($274K)

15 Oct 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Received 42,966 shares by exercise ($167K) · Sold 7,109 shares ($167K)

30 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Acquired 2 Put Option (right to sell) (Open Market Purchase) ($577K) · Disposed of 2 Call Option (obligation to sell) (Open Market Sale) ($577K)

19 Sep 2014 Form 4/A: Thomas, McNerney & Partners Ii L.p., Director and 2 others

Received 65,839 shares by exercise or conversion ($255K) · Returned 12,400 shares to the issuer ($255M)

19 Sep 2014 Form 4/A: Zisson Alex, Director

Received 65,839 shares by exercise or conversion ($255K) · Returned 12,400 shares to the issuer ($255K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 10,200 shares ($235K) · Sold 12,500 shares ($289K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 8,700 shares ($197K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 17,400 shares ($381K) · Sold 12,200 shares ($271K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 6,300 shares ($135K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 5,400 shares ($112K)

09 Sep 2014 Form 4/A: Cmea Ventures Vii Lp, 10% owner and 1 other

Sold 1,700 shares ($34.9K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support